License Agreements - Additional Information (Details) - USD ($)			1 Months Ended			3 Months Ended			6 Months Ended
	Jul. 13, 2021	Jan. 12, 2021	May 31, 2021	Mar. 31, 2021	Mar. 31, 2019	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
License Revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue						$ 5,000,000			$ 30,500,000
George Washington
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payment								$ 500,000
Percentage of royalty on net sales									6.00%
Percentage of payments received from sublicensee									15.00%
Royalty payments						400,000	$ 500,000		$ 3,200,000	$ 900,000
Harvard
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of royalty on net sales									5.00%
Percentage of payments received from sublicensee									20.00%
Clinical development and regulatory milestones amount payable									$ 15,100,000
Percentage of minimum royalty rate									4.50%
Percentage of maximum royalty based on achievement of annual net product sales thresholds									7.50%
Royalties payments						1,500,000			$ 1,600,000
Payments related to clinical development and regulatory milestones						0			0
Paratek
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of royalty on net sales					2.25%
Royalties payments						40,000			$ 100,000
Claim expiration									2023-10
PAION AG
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payment		$ 109,500,000
Upfront cash payment		$ 22,500,000
Percentage of refundable tax withholding		15.00%
PAION AG | Subsequent Event
Research And Development Arrangement Contract To Perform For Others [Line Items]
Supply agreement term	3 years
Everest Medicines Limited
Research And Development Arrangement Contract To Perform For Others [Line Items]
Additional regulatory milestone payments receivable						8,000,000.0			$ 8,000,000.0
Sales milestone payments receivable						20,000,000.0			$ 20,000,000.0
Royalties payable description									Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (1) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (2) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (3) 10 years after the first commercial sale of a product in such jurisdiction in the Everest Territory.
Royalties payable period after first commercial sale of product									10 years
Milestone payments received				$ 3,000,000.0
Everest Medicines Limited | Commercial Supply Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Proceeds from upfront payments			$ 6,800,000
Proceeds from upfront technology transfer payment			4,000,000.0
Proceeds from partial prepayment for XERAVA			2,800,000
Additional technology transfer payment receivable by January 30, 2022			$ 1,000,000.0
Percentage of reimbursed for direct and certain indirect manufacturing costs through December 31, 2023			110.00%
Deferred revenue						2,800,000			$ 2,800,000
Everest Medicines Limited | Commercial Supply Agreement | License Revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue						$ 5,000,000.0			$ 5,000,000.0